Long-Acting Injectable Risperidone Compared with Zuclopenthixol in the Treatment of Schizophrenia with Substance Abuse Comorbidity
Gabriel Rubio,I. Martinez,Guillermo Ponce,Miguel Ángel Jiménez-Arriero,Francisco López-Muñoz,Cecilio Alamo +5 more
Reads0
Chats0
TLDR
Long-acting injectable risperidone was more effective than zuclopenthixol-depot in improving substance abuse and schizophrenia symptoms in subjects with dual diagnosis.Abstract:
Objective:This study aimed to compare the efficacy of long-acting risperidone and zuclopenthixol in subjects with schizophrenia and substance abuse.Method:A total of 115 subjects with schizophrenia...read more
Citations
More filters
Journal ArticleDOI
Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology:
TL;DR: These guidelines from the British Association for Psychopharmacology address the scope and targets of pharmacological treatment for schizophrenia, and cover the pharmacological management and treatment of schizophrenia across the various stages of the illness.
Journal ArticleDOI
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects
Alkomiet Hasan,Peter Falkai,Thomas Wobrock,Jeffrey A. Lieberman,Birte Glenthøj,Wagner F. Gattaz,Florence Thibaut,Hans-Jürgen Möller,Wfsbp Task Force on Treatment Guidelines for Schizophrenia +8 more
TL;DR: These updated guidelines are based on a first edition of the World Federation of Societies of Biological Psychiatry guidelines for biological treatment of schizophrenia published in 2006 and provide evidence-based practice recommendations that are clinically and scientifically meaningful.
Journal ArticleDOI
BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP
TL;DR: The guidelines primarily cover the pharmacological management of withdrawal, short- and long-term substitution, maintenance of abstinence and prevention of complications, where appropriate, for substance abuse or harmful use or addiction as well management in pregnancy, comorbidity with psychiatric disorders and in younger and older people.
Journal ArticleDOI
Treatment of Substance Abusing Patients with Comorbid Psychiatric Disorders
TL;DR: Clozapine appears to be the most effective of the antipsychotics for reducing alcohol, cocaine and cannabis abuse among patients with schizophrenia and highly structured therapy programs that integrate intensive outpatient treatments, case management services and behavioral therapies are most effective for treatment of severe comorbid conditions.
Journal ArticleDOI
Schizophrenia and Co-Occurring Substance Use Disorder
TL;DR: A 29-year-old Caucasian man was brought to the emergency department by the police after he was found wandering barefoot through the snow on Main Street after he had relapsed to heavy use of alcohol and cannabis and appeared to be responding to internal voices.
References
More filters
Journal ArticleDOI
The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia
TL;DR: Review of five studies involving the PANSS provided evidence of its criterion-related validity with antecedent, genealogical, and concurrent measures, its predictive validity, its drug sensitivity, and its utility for both typological and dimensional assessment.
Journal ArticleDOI
Comorbidity of Mental Disorders With Alcohol and Other Drug Abuse. Results From the Epidemiologic Catchment Area (ECA) Study
Darrel A. Regier,Mary E. Farmer,Donald S. Rae,Ben Z. Locke,Samuel J. Keith,Lewis L. Judd,Frederick K. Goodwin +6 more
TL;DR: Comorbidity of addictive and severe mental disorders was highest in the prison population, most notably with antisocial personality, schizophrenia, and bipolar disorders.
Journal ArticleDOI
An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index.
TL;DR: The use of the ASI is suggested to match patients with treatments and to promote greater comparability of research findings, suggesting the treatment problems of patients are not necessarily related to the severity of their chemical abuse.
Journal ArticleDOI
Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia
TL;DR: In this paper, a novel mechanism for regulating dopamine activity in subcortical sites and its possible relevance to schizophrenia is proposed, which is based on the regulation of dopamine release into sub cortical regions occurring via two independent mechanisms: (1) transient or phasic dopamine release caused by dopamine neuron firing, and (2) sustained, "background" tonic release regulated by prefrontal cortical afferents.